The purpose of this study was to evaluate the regulatory effects of Huangqian-biobacteria compound preparation on liver health and related metabolic disorders in middle-aged and elderly people, observe its effects on liver function indexes, basal metabolic rate, markers of oxidative stress, inflammatory factors and intestinal microecology, and evaluate the incidence of adverse reactions in subjects during the 3-month intervention period.
None
People who are allergic to any of the pharmaceutical ingredients used in this study; A history of alcohol abuse (drinking more than 14 units of alcohol per week :1 unit = 285mL for beer, 25mL for spirits, 100mL for wine);
Patients who received probiotics within 1 month before taking the experimental drug;
Recent history of gastrointestinal bleeding, obstruction, perforation, tumor and other serious organic diseases;
Aminotransferase index > 3 times the normal value;
Wecare Probiotics Co., Ltd.
Lead sponsor